Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-7386 (masofaniten) + enzalutamide vs enzalutamide in metastatic castration-resistant prostate cancer
2023-509336-25-00Phase 2Completed
- Sponsor
- ESSA Pharma
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised trial in metastatic castration-resistant prostate cancer (mCRPC) comparing EPI-7386 (masofaniten) + enzalutamide with Enzalutamide alone (2 arms). Primary endpoints: Dose-limiting toxicities (DLTs) in Phase 1, Treatment-emergent adverse events (TEAEs) in Phase 1 and 3 more. Started Apr 2024; status: completed.
02
Drugs
masofanitenenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2023-509336-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509336-25-00.